Benzinga | Oct 7, 2021 11:11AM EDT

AbbVie Presents New Upadacitinib Data In Atopic Dermatitis

* AbbVie Inc (NYSE:ABBV) announced new analyses from the Phase 3 Rinvoq (upadacitinib) atopic dermatitis clinical trial program.

* Data were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.

* One analysis showed a greater proportion of patients treated with Rinvoq (15 mg or 30 mg; once daily) with or without topical corticosteroids achieved 75% improvement in the Eczema Area Severity Index (EASI 75) at week 16 compared to placebo regardless of age, sex, race, weight, disease severity and previous exposure to systemic therapy.

* An additional analysis showed that more patients treated with Rinvoq 30 mg achieved EASI 75 at week 16 than dupilumab when measured in four body regions.

* No new safety risks were observed.

* Price Action: ABBV stock is down 0.03% at $108.81 during the market session on the last check Thursday.

* Editor's Note: The story has been updated with additional details.